Efficacy & Safety of Prophylaxis With Bemiparin in Cancer Patients With a Central Venous Catheter (BECAT)
Status:
Terminated
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of the subcutaneous
administration for 45 days of Bemiparin (3,500 UI/day) in cancer patients with a CVC, to
prevent CVC-related deep venous thrombosis (CVC-DVT)
Phase:
Phase 3
Details
Lead Sponsor:
Clinica Universidad de Navarra, Universidad de Navarra